MA54458A - Formes cristallines et formes salines d'un inhibiteur de kinase - Google Patents

Formes cristallines et formes salines d'un inhibiteur de kinase

Info

Publication number
MA54458A
MA54458A MA054458A MA54458A MA54458A MA 54458 A MA54458 A MA 54458A MA 054458 A MA054458 A MA 054458A MA 54458 A MA54458 A MA 54458A MA 54458 A MA54458 A MA 54458A
Authority
MA
Morocco
Prior art keywords
crystalline
kinase inhibitor
salt forms
salt
forms
Prior art date
Application number
MA054458A
Other languages
English (en)
Inventor
Melanie Janelle Bevill
Frenel Demorin
Courtney S Johnson
Stephan D Parent
Khalid Shah
Sagar Shakya
Peter Wong
Original Assignee
Exelixis Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Exelixis Inc filed Critical Exelixis Inc
Publication of MA54458A publication Critical patent/MA54458A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MA054458A 2018-12-13 2019-12-12 Formes cristallines et formes salines d'un inhibiteur de kinase MA54458A (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862779430P 2018-12-13 2018-12-13
US201962856469P 2019-06-03 2019-06-03

Publications (1)

Publication Number Publication Date
MA54458A true MA54458A (fr) 2021-10-20

Family

ID=69160358

Family Applications (1)

Application Number Title Priority Date Filing Date
MA054458A MA54458A (fr) 2018-12-13 2019-12-12 Formes cristallines et formes salines d'un inhibiteur de kinase

Country Status (20)

Country Link
US (2) US12017995B2 (fr)
EP (1) EP3894012A1 (fr)
JP (2) JP7509779B2 (fr)
KR (1) KR20210102381A (fr)
CN (1) CN113329790A (fr)
AU (1) AU2019395419A1 (fr)
BR (1) BR112021011333A2 (fr)
CA (1) CA3122840A1 (fr)
CL (1) CL2021001537A1 (fr)
CO (1) CO2021007613A2 (fr)
CR (1) CR20210375A (fr)
GE (1) GEP20247596B (fr)
IL (1) IL283860A (fr)
MA (1) MA54458A (fr)
MX (1) MX2021006951A (fr)
PE (1) PE20211757A1 (fr)
PH (1) PH12021551356A1 (fr)
SG (1) SG11202105949RA (fr)
TW (1) TWI852963B (fr)
WO (1) WO2020123800A1 (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2020007765A (es) * 2018-01-26 2020-09-25 Exelixis Inc Compuestos para el tratamiento de trastornos dependientes de cinasas.
MA56001A (fr) * 2019-06-03 2022-04-06 Exelixis Inc Formes de sel cristallin d'un inhibiteur de kinase
CN115461328A (zh) * 2020-04-30 2022-12-09 埃克塞里艾克西斯公司 用于制备激酶抑制剂的方法
MX2023001298A (es) 2020-07-31 2023-02-22 Exelixis Inc Combinaciones para el tratamiento de cancer.
PE20240223A1 (es) 2020-11-05 2024-02-16 Exelixis Inc Composiciones farmaceuticas de un inhibidor de cinasa
CN112650176B (zh) * 2020-12-22 2022-08-30 天能化工有限公司 一种盐酸解析开停车工序的dcs控制方法
TW202334090A (zh) * 2021-11-03 2023-09-01 美商艾克塞里克斯公司 用於治療激酶依賴性病症之化合物
CN118647603A (zh) 2021-12-22 2024-09-13 埃克塞里艾克西斯公司 激酶抑制剂的结晶形式和盐形式

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE517091T1 (de) 2003-09-26 2011-08-15 Exelixis Inc C-met-modulatoren und verwendungsverfahren
WO2006113546A2 (fr) 2005-04-15 2006-10-26 Neogenix Oncology, Inc. Anticorps monoclonaux recombines et antigenes correspondants contre les cancers du colon et du pancreas
EP2340244A4 (fr) 2008-10-14 2012-07-25 Ning Xi Composés et procédés d'utilisation
EA026425B1 (ru) 2009-01-16 2017-04-28 Экселиксис, Инк. Малатная соль n-(4-{[6,7-бис(метилокси)хинолин-4-ил]окси}фенил)-n'-(4-фторфенил)циклопропан-1,1-дикарбоксамида и ее кристаллические формы для лечения рака
CN102408411B (zh) 2011-09-19 2014-10-22 北京康辰药业股份有限公司 一种含喹啉基的羟肟酸类化合物及其制备方法、以及含有该化合物的药物组合物及其应用
MX370848B (es) 2012-10-04 2020-01-08 Dana Farber Cancer Inst Inc Anticuerpos monoclonales humanos anti-pd-l1 y métodos de uso.
EP3770176A1 (fr) 2013-05-02 2021-01-27 AnaptysBio, Inc. Anticorps dirigés contre la protéine de mort programmée 1 (pd-1)
MX2016010266A (es) 2014-02-14 2017-02-08 Exelixis Inc Formas solidas cristalinas de n-{4-[(6,7-dimetoxiquinolin-4-il)oxi ]fenil}-n'-(4-fluorofenil)ciclopropan-1,1-dicarboxamida, procesos para elaboracion y metodos de uso.
CN104817497B (zh) 2015-03-20 2017-03-08 南京众睿缘生物科技有限公司 一种炔代喹啉衍生物及其制备方法和用途
MX2019012505A (es) 2017-05-26 2019-12-19 Exelixis Inc Formas solidas cristalinas de sales de ciclopropano-1,1-dicarboxam ida de n-{4-[(6,7-dimetoxiquinolin-4-il)oxi]fenil}-n'-(4-fluorofen il), procesos para realizarlas y metodos de uso.
MX2020007765A (es) * 2018-01-26 2020-09-25 Exelixis Inc Compuestos para el tratamiento de trastornos dependientes de cinasas.
MA56001A (fr) * 2019-06-03 2022-04-06 Exelixis Inc Formes de sel cristallin d'un inhibiteur de kinase

Also Published As

Publication number Publication date
CN113329790A (zh) 2021-08-31
US12017995B2 (en) 2024-06-25
CR20210375A (es) 2021-08-18
JP2022512399A (ja) 2022-02-03
BR112021011333A2 (pt) 2021-08-31
PH12021551356A1 (en) 2021-12-06
US20240300897A1 (en) 2024-09-12
US20230029213A1 (en) 2023-01-26
GEP20247596B (en) 2024-02-26
JP7509779B2 (ja) 2024-07-02
JP2024038167A (ja) 2024-03-19
AU2019395419A1 (en) 2021-07-01
MX2021006951A (es) 2021-07-15
TWI852963B (zh) 2024-08-21
CO2021007613A2 (es) 2021-06-21
KR20210102381A (ko) 2021-08-19
WO2020123800A1 (fr) 2020-06-18
IL283860A (en) 2021-07-29
EP3894012A1 (fr) 2021-10-20
CL2021001537A1 (es) 2022-02-04
CA3122840A1 (fr) 2020-06-18
SG11202105949RA (en) 2021-07-29
TW202039440A (zh) 2020-11-01
PE20211757A1 (es) 2021-09-07

Similar Documents

Publication Publication Date Title
MA54458A (fr) Formes cristallines et formes salines d'un inhibiteur de kinase
MA53226A (fr) Sel et formes cristallines d'omecamtiv mecarbil
MA52493A (fr) Sels d'un inhibiteur de fgfr
MA51066A (fr) Inhibiteurs d'intégrine
AR114827A1 (es) Sal sódica de n-((1,2,3,5,6,7-hexahidro-s-indacen-4-il)carbamoil)-1-isopropil-1h-pirazol-3-sulfonamida
MA56001A (fr) Formes de sel cristallin d'un inhibiteur de kinase
MA42606A (fr) Sels d'un inhibiteur de lsd1
MA55614A (fr) Formes cristallines d'inhibiteur de pyridazinone trpc
MA52004A (fr) Inhibiteurs d'o-glycoprotéine-2-acétamido-2-désoxy-3-d-glycopyranosidase
MA46866A (fr) Une forme cristalline d'un inhibiteur de magl
MA55801A (fr) Formes solides d'un inhibiteur de glyt1
MA51619A (fr) Inhibiteurs de la protéine kinase dépendante de l'adn
MA50921A (fr) Sels et formes cristallines d'un modulateur allostérique positif du gabaa
MA54638A (fr) Formes cristallines d'un stimulateur de sgc
MA41827A (fr) Formes solvatées d'un inhibiteur de la tyrosine kinase de bruton
MA56022A (fr) Dérivés d'amino quinazoline servant d'inhibiteurs de p2x3
MA54087A (fr) Sels cristallins d'un inhibiteur de la kallicréine plasmatique
MA53671A (fr) Formes cristallines d'un agoniste du récepteur farnésoïde x
EA202191051A1 (ru) Ингибитор аврора-киназы a для применения для лечения нейробластомы
MA54526A (fr) NOUVELLES FORMES POLYMORPHES D'UN INHIBITEUR DE TGFBeta
MA52935A (fr) Composés inhibiteurs d'oga
MA53546A (fr) Nouvelles formes salines de chlorhydrate d'un inhibiteur de kinase à structure sulfamide
IL281168A (en) Crystal forms of the quinazole compound and its hydrochloride salts
MA54541A (fr) Formes cristallines et salines d'un composé organique et compositions pharmaceutiques associées
MA53648A (fr) Inhibiteurs d'o-glycoprotéine-2-acétamido-2-désoxy-3-d-glucopyranosidase